DaVita Inc. (DVA)
| Market Cap | 11.22B +29.6% |
| Revenue (ttm) | 14.17B +6.4% |
| Net Income | 920.08M +19.2% |
| EPS | 13.55 +38.8% |
| Shares Out | 62.92M |
| PE Ratio | 13.16 |
| Forward PE | 11.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,799 |
| Open | 178.34 |
| Previous Close | 179.28 |
| Day's Range | 178.34 - 178.34 |
| 52-Week Range | 101.00 - 247.49 |
| Beta | 0.86 |
| Analysts | Hold |
| Price Target | 222.29 (+24.64%) |
| Earnings Date | Oct 29, 2026 |
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In... [Read more]
Financial Performance
In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for DVA stock is "Hold." The 12-month stock price target is $222.29, which is an increase of 24.64% from the latest price.
News
DaVita Transcript: 8th Annual Wolfe Research Healthcare Conference
Q3 volume missed expectations due to hospitalization-related missed treatments, while census was slightly better than expected; new dialyzers are rolling out to most eligible patients in November. For Q4, calendar headwinds and rising RPT QoQ shape the outlook; IKC and international opportunities remain in focus.
Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating DaVita Inc. (NYSE: DVA) (“DaVita” or the “Co...
DaVita Transcript: UBS Global Healthcare Conference
International operations are on plan and IKC is expected to contribute ~2% to 2026 operating income growth, while U.S. dialysis faces cost and payer-mix pressure. For 2027, pharmaceutical savings and stronger volume are expected to help offset reimbursement headwinds.
Did You Lose Money on DaVita Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on DaVita Inc. ("DaVita" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reporte...
DaVita Inc. to Participate in Upcoming Investor Conferences
DENVER, Nov. 3, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its Chief Financial Officer, Joel Ackerman, and its Group Vice President of Investor Relations, Nic Eliason, will part...
Lost Money on DaVita Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--DaVita Inc. ("DaVita" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investiga...
DaVita price target raised to $228 from $220 at TD Cowen
TD Cowen raised the firm’s price target on DaVita (DVA) to $228 from $220 and keeps a Buy rating on the shares. The firm updated its model following Q3 results…
DaVita price target raised to $287 from $270 at UBS
UBS analyst AJ Rice raised the firm’s price target on DaVita (DVA) to $287 from $270 and keeps a Buy rating on the shares. DaVita beat Q3 expectations on continued…
DaVita price target lowered to $216 from $224 at Barclays
Barclays analyst Andrew Mok lowered the firm’s price target on DaVita (DVA) to $216 from $224 and keeps an Equal Weight rating on the shares.
DaVita Earnings Call Transcript: Q3 2026
Q3 adjusted operating income was $561 million and adjusted EPS was $3.82. IKC raised its FY2026 outlook, while higher technology costs and ACA-related mix pressure temper results; expanded HD rollout begins in November.
DaVita Earnings release: Q3 2026
DaVita released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
DaVita Quarterly report: Q3 2026
DaVita has published its Q3 2026 quarterly earnings report on October 29, 2026.
DaVita reports Q3 EPS $3.82, consensus $3.57
Reports Q3 revenue $3.58B, consensus $3.52B.
DaVita narrows FY26 adjusted EPS to $14.30-$15.20 from $14.10-$15.20
FY26 consensus $14.82. Narrows FY26 adjusted operating income view to $2.175B-$2.25B from $2.15B-$2.25B.
DaVita Inc. 3rd Quarter 2026 Results
DENVER, Oct. 29, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter end...
DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks
Nearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with chro...
TD says HHS charitable activity review recommendation near-term risk for DaVita
TD Cowen notes that HSS “unexpectedly” released a “Kidney Care National Plan,” making a number of policy recommendations. The firm sees the charitable activity review recommendation as the largest nea...
Investors unlikely to find positive Fresenius take from HHS plan, says JPMorgan
After HHS published a new Kidney Care National Plan, JPMorgan said bears will focus on the strong rhetoric around the large incumbent providers, Fresenius Medical (FMS) and DaVita (DVA), and…
DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call
DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p...
DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to translating innovation into better care DENVER, Oct. 15, 2026 /PRNewswire/ -- Da...
DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early
Patients encouraged to confirm treatment schedules, prepare emergency supplies and contact DaVita for assistance DENVER, Oct. 8, 2026 /PRNewswire/ -- As Hurricane Isaias approaches the Gulf Coast and ...
Alebund Pharmaceuticals Announces 2026 Interim Results
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its una...
DaVita enters care pact with Humana for chronic kidney disease patients
DaVita (DVA) announced a new value-based care agreement to deliver coordinated care to Humana (HUM) Medicare Advantage members with chronic kidney disease stages 3B-5. The company said, “Launched July...
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based ca...
DaVita price target lowered to $215 from $250 at Truist
Truist lowered the firm’s price target on DaVita (DVA) to $215 from $250.